Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : MLN9708
CAS No.: 1239908-20-3
Catalog No.: PC-42595Not For Human Use, Lab Use Only.
Ixazomib citrate (MLN9708) is a potent, selective, orally bioavailable proteasome inhibitor with IC50 of 3.4 nM.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 50 mg | $128 | In stock | |
| 100 mg | $198 | In stock | |
| 200 mg | Get quote | ||
| 1 g | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Ixazomib citrate (MLN9708) is a potent, selective, orally bioavailable proteasome inhibitor with IC50 of 3.4 nM.
Ixazomib citrate (MLN9708) binds to and inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with Ki of 0.93 nM, weakly inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50 of 31 and 3,500 n M).
Ixazomib citrate (MLN9708) inhibits growth and induces apoptosis in MM cells.
Ixazomib citrate (MLN9708) shows improved antitumor activity in models of lymphoma compared with bortezomib.
| M.Wt | 517.1216 | |
| Formula | C20H23BCl2N2O9 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
1,3,2-Dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo- |
|
1. Kupperman E, et al. Cancer Res. 2010 Mar 1;70(5):1970-80.
2. Chauhan D, et al. Clin Cancer Res. 2011 Aug 15;17(16):5311-21.
3. Lee EC, et al. Clin Cancer Res. 2011 Dec 1;17(23):7313-23.
4. Tian Z, et al. Blood. 2012 Nov 8;120(19):3958-67.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
